ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO1062

Plasma Fibroblast Growth Factor 21 (FGF21) Concentration in Patients After Kidney Transplantation

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Adamczak, Marcin, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
  • Bartmanska, Magdalena, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
  • Wiecek, Andrzej, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
Background

Fibroblast growth factor 21 (FGF21) is a protein hormone involved in the regulation of metabolism and energy expenditure. Results of clinical studies suggest that plasma FGF21 concentration increases with the progression of chronic kidney disease (CKD). The aim of the present clinical study was to analyze the effect of successful kidney transplantation (KTx) on plasma FGF21 concentration and to study the factors related to plasma FGF21 concentration in patients long-term after KTx.

Methods

The first part of the study, i.e. the 6 months prospective observation, included 40 CKD patients directly before KTx [26 women and 14 men aged 47.0 (39.2 – 54.0) years]. In the second part of the study 184 patients long-term after KTx [72 women and 112 men aged 52.0 (48.0 – 54.0) years] and 50 healthy subjects (HS) [28 women and 22 men aged 52.0 (48.0 – 58.0) years] were enrolled. FGF21 plasma concentration was measured using Human FGF-21 ELISA (BioVendor R&D). Results were presented as median and 95% CI.

Results

In CKD patients directly before KTx plasma FGF21 concentration were significantly higher than in HS [1013.0 (689.6–1635.8) pg/ml vs 239.5 (219.0–294.5) pg/ml respectively; p<0.001]. At 14, 30 days and 6 months after KTx, a significant decrease of plasma FGF21 was observed [322.5 (197.3– 579.6) pg/ml; 355.0 (268.5–547.6) pg/ml; 344.0 (264.1–405.6) pg/ml (p<0.001), respectively]. In patients long-term after KTx, a negative correlation was found between plasma FGF21 concentration and estimated glomerular filtration rate and a positive correlations between plasma FGF21 concentration and BMI and serum concentration of triglycerides, insulin, interleukin 6, CRP and cystatin C.

Conclusion

1. In CKD patients plasma FGF21 concentration measured directly before KTx is significantly higher than in HS. 2. Successful KTx leads to a significant decrease of plasma FGF21 concentration. 2. Plasma FGF21 concentration in patients long-term after KTx is related to the degree of graft function impairment and several metabolic abnormalities of these patients.

Funding

  • Government Support – Non-U.S.